Navigation Links
Enhancing Survival Rate Of Lung Cancer Patients

Investigators in an international study found the survival rate of non-small-cell lung cancer patients after its removal // improved with cisplatin-based adjuvant chemotherapy. Cisplatin is an anti-neoplastic medication that interferes with the growth of cancer cells and slows their growth and spread in the body.

Researchers randomly assigned 1,867 patients to receive either three or four cycles of cisplatin-based chemotherapy or observation. In addition to cisplatin, the drug etoposide was given to about 56 percent of patients; the drug vinorelbine was given to about 26 percent of patients; vinblastine was given to 11 percent of patients, and vindesine was given to nearly 6 percent of patients. Of the 932 patients assigned to chemotherapy, nearly 73 percent received at least 240 milligrams of cisplatin per square meter of body-surface area.

Results of the study showed that after five years, patients assigned to chemotherapy had a significantly higher survival rate at 44.5 percent than those assigned to observation who had a 40.4 survival rate at five years. Patients assigned to chemotherapy also had a significantly higher disease-free survival rate at 39.4 percent than those assigned to observation with 34.3 percent.

Thus researchers say their results indicate that roughly 7,000 deaths from non-small-cell carcinoma would be averted annually with the use of adjuvant cisplatin-based chemotherapy.
'"/>




Page: 1

Related medicine news :

1. Enhancing Infants Immune System
2. Rescuing Injured Hearts by Enhancing Regeneration
3. Saudi Arabia for Enhancing Health Sector Ties with India
4. Elevate End- Of- Life Experience by Enhancing Quality of Hospice Care
5. Testosterone Cream – Ineffective in Enhancing Libido in Female Cancer Survivor
6. Long-Term Survival can be Predicted by a Simple Lung Test
7. Hepatitis G May Boost HIV Survival
8. Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy"
9. Longer Lung Cancer Survival
10. ICU Survival can be improved by Antibiotic use
11. Vasopressin Found To Boost Survival In Sudden Cardiac arrest

Post Your Comments:
(Date:11/27/2009)...all/--TheGymboreeCorporation(Nasdaq: GYMB )announc...MX23rdInvestorProgram,whichwillbeheldattheMayFairH...11:45a.m.GMT. ,, TolistentoalivebroadcastofTheG...easelogontowww.gymboree.com,clickon"OurCompany"att...ndthen"ConferenceCalls&Webcasts."Thewebcastwil...
(Date:11/27/2009)...e-FirstCall/--ShamirOpticalIndustryLtd.(Nasdaq: SH...ctsandtechnologytotheophthalmiclensmarket,announce...istributioninanaggregateamountofUS$10million(appro...presentativerateofexchange),orapproximatelyUS$0.60...esentativerateofexchange)perordinarysharebasedonth...
(Date:11/27/2009)... economic burdens, study predicts , , FR...ople with diabetes in the United States is expecte...edicts. , That would bring the total by 2034 to...om 23.7 million today. , , At the same time, the..., the study also warns, rising from an estimated $...
(Date:11/27/2009)...gual coloring books designed for children ages 2 t...o educate - inform parents and children alike on a...rs to ABC,S and a host of other topics. , ...27, 2009 -- Today’s children have enough gad...ur of the day, but one of the oldest and simplest ...
(Date:11/26/2009)...ndfluseasonuponus,it,smoreimportantthanevertoemplo...idillness. ,, "Weneedtobeproactivenotonlytokeep...,resick,"saidEileenFinerty,RN,MS,CIC(certifiedinin...landoccupationalhealthatHospitalforSpecialSurgery(...soneofthelowestinfectionratesofanyhospitalinthecou...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3
...swire/ -- WuXi PharmaTech (NYSE:,WX), a leading ph...earch,and development outsourcing company with ope...o announce that the distinguished Stanford Univers...: http://www.newscom.com/cgi-bin/prnh/20040705/CN...
... May 20 Accelerate Brain Cancer,Cure ( http://www...on its,website from leading brain cancer specialis...rain cancer study, as well as valuable guidance fo...ain cancer research and treatment,including:, Dr....
...linic researchers found that the frequency with wh...ssociated pneumonia (VAP) is approximately the sam...yo Clinic compared to the average VAP-risk rate fo...rong across the U.S. in intensive care units, whic...
...scious after swallowing Aqua Dots beads led to a v...t the time, it was widely reported that the potent...used in place of the benign but more expensive 1,5...eports, finding that Aqua Dots contained no 1,5-PD...
...wire/.- Speaker Nancy Pelosi,issued the following ...ennedy,s health:, "The news of Senator Kennedy,s ... Kennedy is a champion for health care for all Ame...e., "Our thoughts and prayers are with him, with ...
... draws specialists from across the ...al Werks, a leading provider of,ceramic components...ices,announced today that the Company will provide...,of disorders of the spine will convene at the Pal...
Other Medicine News:Health News:Stanford Professor Barry M. Trost Visits WuXi PharmaTech and Gives Two Seminars 2Health News:Brain Cancer Science and Treatment Information 2Health News:Intensive care units' prevention of pneumonia in critically-ill patients generally strong 2Health News:Study finds that recalled Aqua Dots did contain poisonous chemical 2Health News:C5 Medical Werks Joins in Sponsoring SpineWeek 2008 in Geneva, Switzerland 2
(Date:11/25/2009)...HAM,Mass.,Nov.25/PRNewswire/--AccordingtoMillenniu...hnologymarketintelligence,thenearly$3billionUSmark...owthoverthenextfiveyearsdespitetherecenteconomicsl...tfindsthatthismarketwillremainhighlydynamicoverthe...ddevicesinpreviouslyunderservedsegmentsofthetrauma...
(Date:11/25/2009)...T,TheNetherlandsandJOHANNESBURG,November25/PRNewsw...xisDiscoveryannouncedtoday,thattheyhavesignedacoll...rvices. , Pyxis,sworldclasscomputationalchemi...emba,sservicedivisiontoprovidemedicinaland,synthet...,internationalclientnetwork.iThembaPharmaceutical...
(Date:11/24/2009)...NE,Calif.,Nov.24/PRNewswire-FirstCall/--Endologix,...eatmentsforaorticdisorders,announcedtodaythatithas...hepatentinfringementlawsuitbroughtagainstitinOctob...sDistrictCourtinIndianapolis,Indiana. ,, Endolo...itedStatesPatentandTrademarkOffice(USPTO)conductsp...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2AMA Honors IL Ophthalmologist Manus C Kraff M D for Volunteer Eye Care for Military Members 60903 1AMA Honors IL Ophthalmologist Manus C Kraff M D for Volunteer Eye Care for Military Members 60903 2AMA Honors Medical Society Executives 60901 1AMA Honors Medical Society Executives 60901 2AMA Has Chance to Rescind Support of HR 3962 3B AMA Shout Out from Public Urges Doctors to Answer to PATIENTS Not AMA Leadership 60899 1
...--(BUSINESS WIRE)--May 2, 2007 - Acorda Therapeuti...om a Phase 3 clinical trial,of Fampridine-SR in pe...Academy of Neurology meeting. Andrew Goodman, M.D.... University of,Rochester, presented top-line resul...d clinician and subject global impressions.,Dr. Go...
...OD CITY, Calif., May 02, 2007 /PRNewswire-FirstCal...that a presentation was,made today at the 20th Int...held in Palm Springs, California, on a,non-nucleos...iscovered by Genelabs. , The oral presentation was...of Medicinal Chemistry at Genelabs, entitled,"GL59...
Other Medicine Technology:Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 2Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 3
Access Vitamin B12
...ked immunosorbent assay (ELISA) for the semi-quant... in human serum. The presence of ANA can be used i...oratory tests to aid in the diagnosis of rheumatic...gren's syndrome, scleroderma, and mixed connective...
...s that are compatible with multichannel pipettors,...ber of pipetting steps required to prepare and pla... Immuno Concepts for more information about this p... noted with an * after the catalog number and are ...
... to screen out patients negative for antinuclear a...mic rheumatic diseases such as Systemic lupus eryt...tive tissue disease, progressive systemic sclerosi... Raynaud's phenomenon. They can also be used in co...
Medicine Products: